Sorafenib

Catalog No.S7397 Synonyms: BAY 43-9006

Sorafenib Chemical Structure

Molecular Weight(MW): 464.82

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 62 Publications

9 Customer Reviews

  • Inhibition of the MAPK signaling pathway results in downregulation of Plk-1 protein expression. (a) WB analysis for Plk-1 protein after treatment of human melanoma cell lines M14 and WM-115 with MEK 1/2 inhibitor PD98059 (10 μM), JNK inhibitor (16 μM), p38 inhibitor SB203580 (20 μM), and multikinase inhibitor sorafenib (10 μM) for 48 h showing significant reduction in the expression of Plk-1 protein after 48 hours. (b) Annexin V/PI staining of cells treated with MAPK inhibitors and induction of apoptosis. JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MEK 1/2, mitogen-activated protein kinase kinase 1/2; Plk-1, polo-like kinase 1; WB, western blot.

    J Invest Dermatol 2011 131, 1886–1895. Sorafenib purchased from Selleck.

    (A) were exposed to 200 uM gentamicin for various time periods. Immunoreactivity for phosphorylated JNK (green) and c-Jun (blue) in hair cells increased in a time-dependent manner. B. Hair cells from explants pre-treated with 500 nM sorafenib displayed a near complete inhibition of JNK activation at all time points analyzed.

    J Neurosci 2013 33(7), 3079-93. Sorafenib purchased from Selleck.

  • Sorafenib in combination with metformin or the AMPK activator salicylate enhances AMPK activation. a, b, AMPK activation with the combination of sorafenib and metformin in LKB1 mutant KRAS mutant (A549 and H460) NSCLC cells (a), LKB1 wild-type KRAS mutant (H358) (b, left panel) or LKB1 mutant KRAS wild-type (H838) NSCLC cells (b, right panel). Cells were treated for 48 hr with sorafenib (1-3 uM), metformin (1–1.5 mM) or the combination of sorafenib and metformin with the same concentrations as were used for the individual treatments. c, AMPK activation with the combination of sorafenib and salicylate in LKB1 mutant KRAS mutant (A549 and H460) or LKB1 mutant KRAS wild-type (H838) NSCLC cells. Cells were treated for 48 hr with sorafenib (1–3 uM), salicylate (1–1.5 mM) or the combination of sorafenib and salicylate with the same concentrations as were used for the individual treatments. Cell lysates were harvested for western blot analysis and probed with the indicated antibodies.

    Int J Cancer 2012 10.1002/ijc.29113.. Sorafenib purchased from Selleck.

    Involvement of EV linc-VLDLR in tumor cell responses to chemotherapy. Cells were incubated with sorafenib, camptothecin, or doxorubicin. EVs were obtained after 24 hours, and qRT-PCR was performed for linc-VLDLR. The bars represent the mean ?SEM of the increase in cell viability from 3 independent studies. *, P < 0.05.

    Mol Cancer Res 2014 12(10), 1377-87. Sorafenib purchased from Selleck.

  • HCC cell-derived exosomes reverse sorafenib-induced apoptosis in hepatoma carcinoma cells in vivo. a Tumors from mice treated with PBS (Control), sorafenib (Sora), sorafenib + LO2-exosomes (Sora + LO2 exo), sorafenib + MHCC-97 L-exosomes (Sora + 97 L exo), and sorafenib + MHCC-97H-exosomes (Sora + 97H exo) were paraffin-embedded and sectioned, followed by staining of apoptotic cell by using TUNEL assays.

    J Exp Clin Cancer Res, 2016, 35(1):159. Sorafenib purchased from Selleck.

    Sorafenib and PX-866 interact to suppress tumor growth in vivo. Mice were PO administered vehicle diluent, sorafenib (25 mg/kg), PX-866 (2 mg/kg), or the drug combination QD for 3 days. Animals were monitored daily and tumor volume determined every fifth day. Tumors from animals were isolated at day 15 and fixed, sectioned (10-um), and stained against proliferation (Ki67 staining), phospho-ERK1/2 and phospho-AKT staining, the levels of tumor cell apoptosis/cleaved caspase 3, as well as with H&E and 4′,6-diamidino-2-phenylindole (DAPI).

    Mol Pharmacol 2013 84(4), 562-71. Sorafenib purchased from Selleck.

  • Effects of sorafenib or sunitinib on LicA-induced cell death, ER stress responses, PLCc1, Ca2+, and ROS in HepG2 cells. HepG2 cells were pretreated with sorafenib or sunitinib for 1 h, then treated with LicA or TG for 1 h (for P-eIF2a and P-PLCc1) or 24 h (for CHOP, ATF6a(p90), and caspase-4). The cell lysates were subjected to Western blot analyses using antibodies against CHOP, ATF6a(p90), caspase-4(C), P-eIF2a, and b-actin.

    Apoptosis 2014 19(4), 682-97. Sorafenib purchased from Selleck.

    PLoS One 2013 8(1), e54595. Sorafenib purchased from Selleck.

  • (C) Western blotting revealed the expression levels of p-AKT, p-ERK1/2 and cleaved PARP in HUH-7 and R-HUH-7 HCC cell lines, these cell lines were treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h. (D) Western blotting revealed the expression levels of p-AKT, p-ERK1/2 and cleaved PARP in SK-HEP-1 and R-SK-HEP-1 HCC cell lines, these cell lines were treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h. (E) HUH-7 hepatoma cells treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h; proportions of apoptotic cells were calculated after cell cytotoxicity assay. (F) SK-HEP-1 hepatoma cells treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h; proportions of apoptotic cells were calculated after cell cytotoxicity assay. Data were expressed as mean ± standard deviation of each experiment in triplicate. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. Sorafenib purchased from Selleck.

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
Targets
Raf-1 [1]
(Cell-free assay)
mVEGFR2(Flk1) [1]
(Cell-free assay)
mVEGFR3 [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
B-Raf (V599E) [1]
(Cell-free assay)
6 nM 15 nM 20 nM 22 nM 38 nM
In vitro

Sorafenib inhibits both wild-type and V599E mutant B-Raf activity with IC50 of 22 nM and 38 nM, respectively. Sorafenib also potently inhibits mVEGFR2 (Flk-1), mVEGFR3, mPDGFRβ, Flt3, and c-Kit with IC50 of 15 nM, 20 nM, 57 nM, 58 nM, and 68 nM, respectively. Sorafenib weakly inhibits FGFR-1 with IC50 of 580 nM. Sorafenib tosylate is not active against ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-Met, PKB, PKA, cdk1/cyclinB, PKCα, PKCγ, and pim-1. Sorafenib markedly inhibits VEGFR2 phosphorylation in NIH 3T3 cells with IC50 of 30 nM, and Flt-3 phosphorylation in HEK-293 cells with IC50 of 20 nM. Sorafenib potently blocks MEK 1/2 and ERK 1/2 phosphorylation in most cell lines but not in A549 or H460 cells, while having no effect on inhibition of the PKB pathway. Sorafenib inhibits the proliferation of HAoSMC and MDA-MB-231 cells with IC50 of 0.28 μM and 2.6 μM, respectively. [1] In addition to inhibition of the RAF/MEK/ERK signaling pathway, Sorafenib significantly inhibits the phosphorylation of eIF4E and down-regulates Mcl-1 levels in hepatocellular carcinoma (HCC) cells in a MEK/ERK-independent manner. Sorafenib inhibits the proliferation of PLC/PRF/5 and HepG2 cells with IC50 of 6.3 μM and 4.5 μM, respectively, and leads to the significant induction of apoptosis. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;ZW|VKSzVyPUCuNFAxODB|MEOg{txO NGnUSVBUSU6JRWK=
MONO-MAC-6 NH\XcGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwMEC0NVgh|ryP NHvVUHhUSU6JRWK=
ALL-PO MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHWwZZZKSzVyPUCuNFMyQDRizszN MnfJV2FPT0WU
NKM-1 NGDz[|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYGxOWp{UUN3ME2wMlA4PDF4IN88US=> NYnNeG9ZW0GQR1XS
CGTH-W-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\oOIFSUUN3ME2wMlI2ODJ{IN88US=> NIfndWtUSU6JRWK=
BB65-RCC NYSyNHk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoCzTWM2OD1yLkS3NFc{KM7:TR?= NYD6PZA6W0GQR1XS
NOS-1 M{fVOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mle1TWM2OD1yLkW2N|Yh|ryP NFPGO|NUSU6JRWK=
SH-4 M3v1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\mTWlEPTB;MD62OVYyOyEQvF2= NVTQbmE3W0GQR1XS
HOP-62 MnXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HFWmlEPTB;MD64OVA5QCEQvF2= NIHDXW9USU6JRWK=
HCC2998 NUCwVFk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mki0TWM2OD1yLki4PFE5KM7:TR?= MXLTRW5ITVJ?
GDM-1 NF3TUVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\0dGlEPTB;MD65NFY6QCEQvF2= NWH1dXRKW0GQR1XS
KM12 NVnDUnRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3KbWNKSzVyPUGuNFIxQThizszN M3zp[3NCVkeHUh?=
LB2518-MEL MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPNSmZuUUN3ME2xMlIxQDB7IN88US=> M4XSeHNCVkeHUh?=
NCI-H1436 M2D2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rYTWlEPTB;MT6yNVY4QCEQvF2= NFPEN|dUSU6JRWK=
EM-2 NIL3VVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\iNmlEPTB;MT6zOVU4QCEQvF2= MUDTRW5ITVJ?
LAMA-84 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\jTWM2OD1zLkO3OlQ5KM7:TR?= MkHmV2FPT0WU
KG-1 NFH5NIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrnRYNvUUN3ME2xMlQ4QTN3IN88US=> MoTnV2FPT0WU
A388 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTFwNUmxOlUh|ryP MkPsV2FPT0WU
no-10 NX\iZlNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzSdJg3UUN3ME2xMlYyPzJ4IN88US=> M2HkZ3NCVkeHUh?=
SF126 M1nC[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1e4UGlEPTB;MT62N|gyOiEQvF2= NIfUPWFUSU6JRWK=
MEG-01 M3TFV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HiWWlEPTB;MT64NFk5KM7:TR?= Mk\hV2FPT0WU
A3-KAW NGXZZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;6XmlEPTB;MT64PFQzKM7:TR?= M3TmWHNCVkeHUh?=
D-247MG NVrR[YhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTJwMUS0PEDPxE1? MUHTRW5ITVJ?
OVCAR-4 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7CTWM2OD1{LkKxN|k{KM7:TR?= Ml3LV2FPT0WU
NCI-SNU-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHX6NFZKSzVyPUKuN|E3OiEQvF2= NWfMdnIxW0GQR1XS
NCI-H2171 MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljtTWM2OD1{LkO5O|Y1KM7:TR?= NHn5XXpUSU6JRWK=
SIG-M5 MnrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLhTWM2OD1{LkSyNlQzKM7:TR?= NILhfmJUSU6JRWK=
BE-13 MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfHTWM2OD1{Lk[5OlA6KM7:TR?= MV7TRW5ITVJ?
K052 M1vCfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPJTWM2OD1{Lke0OlE3KM7:TR?= NEDnUm1USU6JRWK=
L-540 NFnwS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPJS3Y1UUN3ME2yMlc2Pzh7IN88US=> M1Pac3NCVkeHUh?=
KMOE-2 MkjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHVSYI4UUN3ME2yMlgyOzVizszN MVrTRW5ITVJ?
MFH-ino NVK3TIdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TwVmlEPTB;Mj65NlE5PSEQvF2= Ml65V2FPT0WU
HL-60 MnPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPaOnl7UUN3ME2zMlA3Ojl7IN88US=> MUjTRW5ITVJ?
HCC2218 NVLKWYk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrqTWM2OD1|LkGyNFA{KM7:TR?= NXjBeFJ[W0GQR1XS
TE-5 M{fpZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;tWVJKSzVyPUOuNVMyPjJizszN NWrlOGVqW0GQR1XS
MZ1-PC NV3lcG5MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PlWGlEPTB;Mz60O|UxQSEQvF2= NHG4R|ZUSU6JRWK=
MRK-nu-1 M2DxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TnS2lEPTB;Mz62NVQ3QCEQvF2= M{L4[3NCVkeHUh?=
MZ7-mel NIfLN5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rBemlEPTB;Mz62OlA6QSEQvF2= MnPxV2FPT0WU
BC-1 NIm5bGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTNwN{SwNkDPxE1? NXXZW213W0GQR1XS
ST486 NH7xTYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NES2UnhKSzVyPUOuPFM3PzNizszN MV3TRW5ITVJ?
KS-1 M{Hifmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1X3dmlEPTB;Mz64PFE6QCEQvF2= MVLTRW5ITVJ?
SK-NEP-1 M2rNPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkK4TWM2OD12LkG2PFE2KM7:TR?= NH6z[29USU6JRWK=
BC-3 NEXoTXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mne3TWM2OD12LkKzN|kyKM7:TR?= NUTUXokxW0GQR1XS
NCI-H1581 NGPv[nhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrEVJpKSzVyPUSuNlg4QThizszN NVPHRlhSW0GQR1XS
MHH-PREB-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFu2RmtKSzVyPUSuOFA1QDRizszN M4nTb3NCVkeHUh?=
NOMO-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTRwNEi5NFUh|ryP NGG5XFZUSU6JRWK=
QIMR-WIL NEHVSo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYflZZp3UUN3ME21MlA4Ojl2IN88US=> NUXBbIRnW0GQR1XS
SF539 M3zHUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;M[2lEPTB;NT6xN|IzPyEQvF2= MlziV2FPT0WU
TE-12 NUnFO2ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XlZ2lEPTB;NT6yOFkzQSEQvF2= MmnzV2FPT0WU
NCI-H510A NVq0U4J7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;CTlBKSzVyPUWuOFE3QDVizszN NVnkWGpqW0GQR1XS
JAR M1PuWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfHTWM2OD13LkWwPFI1KM7:TR?= NWnlTYU5W0GQR1XS
no-11 MnfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmraTWM2OD13LkezOVY5KM7:TR?= NEK3[Y9USU6JRWK=
BV-173 MoHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HMWWlEPTB;NT65OVY5OiEQvF2= MXXTRW5ITVJ?
SR NX\CcW0yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrLWJdjUUN3ME22MlAxPjd6IN88US=> M2C5c3NCVkeHUh?=
MOLT-16 NH3DWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWryTZJVUUN3ME22MlI2OjZ4IN88US=> MnPkV2FPT0WU
MZ2-MEL NE\FVldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37EV2lEPTB;Nj6zNVg{QSEQvF2= M134OHNCVkeHUh?=
SW954 NWrXV|ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTZwNEW4OlYh|ryP MV;TRW5ITVJ?
ML-2 NVi2OlZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTZwNUK4OFkh|ryP NX:2N4w3W0GQR1XS
OCI-AML2 MkTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\6TWM2OD14Lk[xNFYzKM7:TR?= M2TXcXNCVkeHUh?=
SIMA NEn4UoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrRVJNKSzVyPUeuNFAyODFizszN NX;MPYVYW0GQR1XS
DOHH-2 MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2q1WWlEPTB;Nz6wOVY4PiEQvF2= MnWxV2FPT0WU
697 NWLrcXF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXGSmVrUUN3ME23MlA2QTh7IN88US=> M2C1OnNCVkeHUh?=
NB1 NUjjc3VET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LBXWlEPTB;Nz60NFQxPyEQvF2= NFrEUGJUSU6JRWK=
D-392MG NYXxcpA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjBOZlKSzVyPUeuOlI3PjNizszN MX\TRW5ITVJ?
ES8 NEfB[lRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjtd4dKSzVyPUeuO|Y2ODNizszN NHrlXFlUSU6JRWK=
RPMI-8226 Mli1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWCxd3p6UUN3ME23Mlg1PTFzIN88US=> Mlv5V2FPT0WU
IST-MEL1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPLTWM2OD16LkSwNFAzKM7:TR?= MWjTRW5ITVJ?
NB14 M2ewWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUO1d2JDUUN3ME24MlY{OTN|IN88US=> Mni3V2FPT0WU
HD-MY-Z NV32b4NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3SyUWlEPTB;OD62N|c1PiEQvF2= NYj2c4FMW0GQR1XS
TE-10 NUXabFlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml70TWM2OD16Lke2N|U{KM7:TR?= MlLMV2FPT0WU
LC-1F M1rDU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEf6RoNKSzVyPUmuNVA5OzRizszN MXTTRW5ITVJ?
OS-RC-2 Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTwTWM2OD17LkGxNlQ{KM7:TR?= MULTRW5ITVJ?
NCI-SNU-16 M1HieGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\TTWM2OD17LkKxNFI3KM7:TR?= NWLCfJlpW0GQR1XS
SHP-77 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTlwN{G2OlIh|ryP NIDwfpZUSU6JRWK=
A4-Fuk NFS4U2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7qTWM2OD17Lke1OlEh|ryP MWTTRW5ITVJ?
NB6 NGL5eJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjJTWhKSzVyPUmuO|YxOjlizszN NXfudlhNW0GQR1XS
JiyoyeP-2003 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LZbWlEPTB;MUCuOFc1PSEQvF2= Mm\vV2FPT0WU
DMS-114 MoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jaXGlEPTB;MUCuOVQ1OSEQvF2= MVrTRW5ITVJ?
NB7 NUnad4dFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkn5TWM2OD1zMD63OVI3KM7:TR?= M3;zdXNCVkeHUh?=
NCI-H747 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPFR3FKSzVyPUGxMlEzOTZizszN NUnu[FNOW0GQR1XS
HH Mo\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTFzLkO4O|Yh|ryP MmnRV2FPT0WU
EW-18 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XtSWlEPTB;MUGuPVA1PCEQvF2= NFLIVoVUSU6JRWK=
CHP-126 NHXEO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknBTWM2OD1zMT65O|M5KM7:TR?= Mkf0V2FPT0WU
NTERA-S-cl-D1 M{HHVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\MTWM2OD1zMj6wNlc5KM7:TR?= MWrTRW5ITVJ?
DEL NUjFd5JnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mle1TWM2OD1zMj6wPVg2KM7:TR?= MXXTRW5ITVJ?
LU-139 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7ZN2dKSzVyPUGyMlU1OTNizszN NIWzWoZUSU6JRWK=
P30-OHK M{fkSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTF{LkW0O|kh|ryP NV;3R4lJW0GQR1XS
NCI-H1522 MmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mke2TWM2OD1zMj63OFYh|ryP M33ueHNCVkeHUh?=
NCI-H1299 M4rJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrZSIpKSzVyPUGzMlI6OTFizszN MYXTRW5ITVJ?
UACC-257 NVzPeFBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HLb2lEPTB;MUOuOVEzPiEQvF2= NGPocpdUSU6JRWK=
Calu-6 MnvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTF|Lk[wOFYh|ryP NEL4S|JUSU6JRWK=
NCI-H1882 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1i2UmlEPTB;MUOuPFU2PSEQvF2= MmXMV2FPT0WU
BB30-HNC NYLFWmhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPHb3ZKSzVyPUG0MlA3ODlizszN M2jYOHNCVkeHUh?=
ES1 MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjpUHhKSzVyPUG0MlE2PTFizszN MV\TRW5ITVJ?
NCI-H1694 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTF2LkS4NVEh|ryP M17tTHNCVkeHUh?=
IST-SL1 Mlv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rY[WlEPTB;MUSuPVYyPiEQvF2= M3HTeHNCVkeHUh?=
ECC4 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvQR4NKSzVyPUG1MlA2PThizszN NWLHWHhoW0GQR1XS
MDA-MB-134-VI NGi3NmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIX1[XRKSzVyPUG1MlQyOzFizszN MmLXV2FPT0WU
SCH MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nFTmlEPTB;MUWuOFczQCEQvF2= NF;iSmZUSU6JRWK=
SK-N-FI NXi4SZU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zMUGlEPTB;MUWuOlU{PCEQvF2= M1LLRnNCVkeHUh?=
HDLM-2 NFu2[ZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDoTWM2OD1zNj6wO|E1KM7:TR?= NGjQTmlUSU6JRWK=
Ramos-2G6-4C10 NGXW[opIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjBTWM2OD1zNj6xNlk4KM7:TR?= M3\YcXNCVkeHUh?=
EW-24 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrndZVKSzVyPUG2MlE3PjFizszN MWXTRW5ITVJ?
NCI-H2141 NEP3VXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLUZ2JKSzVyPUG2MlE5QSEQvF2= Mo\ZV2FPT0WU
LC4-1 NYLMO5dXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFK4dm9KSzVyPUG2MlYyOTlizszN MlXpV2FPT0WU
HT-144 NXizPHBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPJTWM2OD1zNz6wNFYh|ryP NXPNe|FsW0GQR1XS
SK-MEL-1 Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDhTWM2OD1zNz6wNFczKM7:TR?= M1nMNnNCVkeHUh?=
SCC-15 NHq2UoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTF5LkG2N|gh|ryP Mn\UV2FPT0WU
C8166 M1jpfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorDTWM2OD1zNz62PFM{KM7:TR?= NU\abWlGW0GQR1XS
GOTO NWXJXY1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVznR2J5UUN3ME2xO{45OzR2IN88US=> M1PYVnNCVkeHUh?=
COR-L279 NXHsT|FnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXqyR4hVUUN3ME2xPE4yOzZ{IN88US=> MYTTRW5ITVJ?
K-562 NYnUdo9MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoG1TWM2OD1zOD63NVQ{KM7:TR?= MkH4V2FPT0WU
ES3 NVu0TVZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTF6LkiwOFEh|ryP MY\TRW5ITVJ?
LU-165 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnvWnVKSzVyPUG5MlcxODhizszN MmKxV2FPT0WU
KM-H2 NV7aWGp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlv4TWM2OD1{MD6zNVg1KM7:TR?= MnW4V2FPT0WU
RL MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD4NpZyUUN3ME2yNE46Pjl{IN88US=> NFm0VWVUSU6JRWK=
EW-3 MmjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;XZ3Q1UUN3ME2yNU4yQDh7IN88US=> MYrTRW5ITVJ?
A101D MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvtTWM2OD1{MT6zO|UzKM7:TR?= MUHTRW5ITVJ?
HUTU-80 NIr5PIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjpUWEzUUN3ME2yNU4{QTR4IN88US=> MVnTRW5ITVJ?
NCI-H23 M1fkRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[xO4hKSzVyPUKxMlM6QTJizszN MV\TRW5ITVJ?
PF-382 NFvsb2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLnSIJFUUN3ME2yNU41PDB|IN88US=> MYTTRW5ITVJ?
LB373-MEL-D MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETj[WlKSzVyPUKxMlU3OTVizszN NVzMSpVGW0GQR1XS
TE-8 M3\3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonkTWM2OD1{MT62N|k1KM7:TR?= NFi1bZBUSU6JRWK=
TE-9 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjiT3BKSzVyPUKxMlg2OTNizszN Ml\VV2FPT0WU
Daudi NX;XNHZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIq4[25KSzVyPUKxMlk{ODRizszN NEDIbXVUSU6JRWK=
D-542MG MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHvTWM2OD1{Mj6wNlU3KM7:TR?= MVjTRW5ITVJ?
U-698-M MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXUTo42UUN3ME2yNk41PjB|IN88US=> MUnTRW5ITVJ?
ES6 NXTuNmVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfuOVRQUUN3ME2yNk44OzZ4IN88US=> M1uwS3NCVkeHUh?=
DU-4475 Mm\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzZe4YxUUN3ME2yN{45QDl5IN88US=> M4jZOXNCVkeHUh?=
ECC12 MmjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHpTWM2OD1{ND6yPFA{KM7:TR?= MnT6V2FPT0WU
C2BBe1 M1T6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvBbmdKSzVyPUK0MlMzOzlizszN M1[zR3NCVkeHUh?=
IST-SL2 MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoroTWM2OD1{ND60N|YzKM7:TR?= MWfTRW5ITVJ?
DJM-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfMb3NKSzVyPUK0MlUzOjFizszN NH64OXJUSU6JRWK=
DMS-153 NX3HT4N5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzxTWM2OD1{ND64OlE1KM7:TR?= NWTHRXhtW0GQR1XS
NB13 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moe1TWM2OD1{NT6wNlY2KM7:TR?= NH;nVGRUSU6JRWK=
SK-N-DZ M2PQc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTJ4LkO0NVQh|ryP M3\TPXNCVkeHUh?=
COR-L88 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfPTWM2OD1{Nj61O|k3KM7:TR?= M3zkfXNCVkeHUh?=
LU-65 M2HNU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTJ4Lki1N|Uh|ryP NWPGRoFkW0GQR1XS
TGBC1TKB MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[3T2lEPTB;Mk[uPVgzQCEQvF2= M3rDZnNCVkeHUh?=
THP-1 MnvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4m5NmlEPTB;MkeuNlE1OSEQvF2= NIXROI9USU6JRWK=
ONS-76 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHOTWM2OD1{Nz6zN|Ih|ryP NFfXdHVUSU6JRWK=
LC-2-ad NFfwV5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTJ5Lk[yN|Eh|ryP MYnTRW5ITVJ?
EW-13 NXfheYlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Hw[WlEPTB;MkmuNVc1PiEQvF2= M{iyS3NCVkeHUh?=
MS-1 NVTEfJZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnwSHU1UUN3ME2zNE44Ojd6IN88US=> MlzaV2FPT0WU
NCI-H2227 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjKd2ZKUUN3ME2zNE46QDB4IN88US=> NUThZ|duW0GQR1XS
LXF-289 NV;kVHZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mme0TWM2OD1|MT60OFkzKM7:TR?= M2jIV3NCVkeHUh?=
MC116 MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDTTWM2OD1|Mj6wPFI3KM7:TR?= M3LjRXNCVkeHUh?=
EVSA-T M3jKVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTN{LkK1PFUh|ryP NHzRPVJUSU6JRWK=
CTB-1 NHnxWXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTN|LkGxNFEh|ryP NF\oVI5USU6JRWK=
COLO-320-HSR MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTN|LkG2NFMh|ryP NXPFXIlSW0GQR1XS
NCI-H2196 M4rCOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7pOXlKSzVyPUOzMlI2PTdizszN MYDTRW5ITVJ?
LB2241-RCC NUPM[GhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELnS5JKSzVyPUOzMlMyOzVizszN M364S3NCVkeHUh?=
LS-513 MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Xr[2lEPTB;M{OuPFY{QCEQvF2= MlvVV2FPT0WU
LP-1 M{G5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXFfmpKSzVyPUOzMlk6PTZizszN NXnsc29lW0GQR1XS
A253 M4mzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHqZ5FPUUN3ME2zOE4zOjl4IN88US=> MkXtV2FPT0WU
SK-MM-2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7nWXJVUUN3ME2zOE46PDVzIN88US=> MXfTRW5ITVJ?
NCI-H1963 NUH3dHRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX:5dG5lUUN3ME2zOU4{ODd{IN88US=> MUHTRW5ITVJ?
MMAC-SF NUi4OVQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTN3Lki3PFUh|ryP MVLTRW5ITVJ?
LB831-BLC NXHtd4NpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HteWlEPTB;M{[uNFY2PCEQvF2= MXvTRW5ITVJ?
WSU-NHL NFPqTm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXiZo9QUUN3ME2zOk4yPjRizszN M{\FWXNCVkeHUh?=
CESS MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTN4LkK4OFgh|ryP Mn7qV2FPT0WU
NEC8 NXnie4w6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFf3c5hKSzVyPUO2MlU5OzVizszN MVLTRW5ITVJ?
KNS-42 M3rVdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPCTWM2OD1|Nz6xNlM4KM7:TR?= NIPUdmNUSU6JRWK=
MHH-CALL-2 NELuTpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTN5LkG4NlEh|ryP M4PLfHNCVkeHUh?=
K5 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LQTWlEPTB;M{iuOFMh|ryP MmLRV2FPT0WU
CP66-MEL NUPzc3JkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTN7LkC3N|Mh|ryP M4\1TnNCVkeHUh?=
OPM-2 Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2r2WWlEPTB;M{muPFQ{OiEQvF2= NHO1U5ZUSU6JRWK=
IST-MES1 MnjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVT6NGJCUUN3ME20NE4{ODl4IN88US=> MXzTRW5ITVJ?
EC-GI-10 NEf4RodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTRzLkW4NFUh|ryP NIj4SJhUSU6JRWK=
CTV-1 MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTR{Lki0NFYh|ryP MknPV2FPT0WU
DG-75 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjjTWM2OD12Mz63OVk2KM7:TR?= NXqySnozW0GQR1XS
KNS-81-FD M2fZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTR3LkSwOVgh|ryP NYfIbHRFW0GQR1XS
NCI-H82 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;L[mlEPTB;NEWuOVc2QCEQvF2= MVHTRW5ITVJ?
RPMI-8866 NUe2coR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXnTWM2OD12Nj6xPFc{KM7:TR?= M4HuPXNCVkeHUh?=
ACN MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTjTWM2OD12Nj60N|Qh|ryP NGTHXldUSU6JRWK=
NCI-H1395 NV;qOm5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1uxUmlEPTB;NE[uOFc2PiEQvF2= M3L5T3NCVkeHUh?=
NCI-H209 MkTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTR5LkG0NFUh|ryP NFnjXYlUSU6JRWK=
TGW NFPUb|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzTWo1KSzVyPUS5MlA4QTFizszN NVXMTHgxW0GQR1XS
NCI-H748 MnjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTR7LkS3OVMh|ryP MUDTRW5ITVJ?
EKVX NGPKW29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljsTWM2OD12OT62OlI5KM7:TR?= M{fhWXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Oral administration of Sorafenib (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity. In association with the anti-tumor efficacy, Sorafenib treatment potently inhibits MEK 1/2 phosphorylation and pERK 1/2 levels in HT-29 and MDA-MB-231 xenografts but not in Colo-205 xenografts, and significantly suppresses tumor microvessel area (MVA) and microvessel density (MVD) in MDA MB-231, HT-29 and Colo-205 tumor xenografts. [1] Sorafenib treatment produces dose-dependent growth inhibition of PLC/PRF/5 tumor xenografts in SCID mice with TGIs of 49% and 78% at 10 mg/kg and 30 mg/kg, respectively, consistent with the inhibition of ERK and eIF4E phosphorylation, reduction of the microvessel area, and induction of tumor cell apoptosis. [2] Sorafenib sensitizes bax-/- cells to TRAIL in a dose-dependent manner, through a mechanism involving down-regulating NF-κB mediated Mcl-1 and cIAP2 expression. Combining Sorafenib (30-60 mg/kg) with TRAIL (5 mg/kg) show dramatic efficacy in TRAIL-resistant HCT116 bax-/- and HT29 tumor xenografts. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Biochemical assays:

Recombinant baculoviruses expressing Raf-1 (residues 305–648) and B-Raf (residues 409–765) are purified as fusion proteins. Full-length human MEK-1 is generated by PCR and purified as a fusion protein from Escherichia coli lysates. Sorafenib tosylate is added to a mixture of Raf-1 (80 ng), or B-Raf (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl2, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The Raf kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ[33P]ATP (400 Ci/mol) and incubated at 32 °C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity. Human VEGFR2 (KDR) kinase domain is expressed and purified from Sf9 lysates. Time-resolved fluorescence energy transfer assays for VEGFR2 are performed in 96-well opaque plates in the time-resolved fluorescence energy transfer format. Final reaction conditions are as follows: 1 to 10 μM ATP, 25 nM poly GT-biotin, 2 nM Europium-labeled phospho (p)-Tyr antibody (PY20), 10 nM APC, 1 to 7 nM cytoplasmic kinase domain in final concentrations of 1% DMSO, 50 mM HEPES (pH 7.5), 10 mM MgCl2, 0.1 mM EDTA, 0.015% Brij-35, 0.1 mg/mL BSA, and 0.1% β-mercaptoethanol. Reaction volumes are 100 μL and are initiated by addition of enzyme. Plates are read at both 615 and 665 nM on a Perkin-Elmer VictorV Multilabel counter at ~1.5 to 2.0 hours after reaction initiation. Signal is calculated as a ratio: (665 nm/615 nM) × 10,000 for each well. For IC50 generation, Sorafenib tosylate is added before the enzyme initiation. A 50-fold stock plate is made with Sorafenib tosylate serially diluted 1:3 in a 50% DMSO/50% distilled water solution. Final Sorafenib tosylate concentrations range from 10 μM to 4.56 nM in 1% DMSO.
Cell Research:

[1]

+ Expand
  • Cell lines: MDA-MB-231, and HAoSMC
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to increasing concentrations of Sorafenib tosylate for 72 hours. Cell number is quantitated using the Cell TiterGlo ATP Luminescent assay kit. This assay measures the number of viable cells per well by measurement of luminescent signal based on amount of cellular ATP.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
  • Formulation: Dissolved in Cremophor EL/ethanol (50:50) as 4-fold (4 × stock solution, and diluted to 1 × with water
  • Dosages: ~60 mg/kg
  • Administration: Orally once daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 63 mg/mL warmed (135.53 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
In vivo Add solvents individually and in order:
5% DMSO+45% PEG 400+ddH2O
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 464.82
Formula

C21H16ClF3N4O3

CAS No. 284461-73-0
Storage powder
in solvent
Synonyms BAY 43-9006

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00727233 Completed Neurofibromatosis Type I|Plexiform Neurofibroma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 8, 2008 Phase 1
NCT02989870 Not yet recruiting HepatoCellular Carcinoma|Unresectable HepatoCellular Carcinoma|Liver Cancer H. Lee Moffitt Cancer Center and Research Institute|National Comprehensive Cancer Network April 30, 2017 Phase 1
NCT01445080 Completed Leukemia|With AML and FLT3-ITD Mutations National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 23, 2006 Phase 1
NCT01434602 Recruiting Brain Tumor|Glioblastoma|Anaplastic Glioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 21, 2015 Phase 1|Phase 2
NCT02988440 Not yet recruiting Hepatocellular Carcinoma Novartis Pharmaceuticals|Novartis May 2017 Phase 1
NCT03037437 Not yet recruiting Hepatocellular Cancer The University of Texas Health Science Center at San Antonio January 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Raf Signaling Pathway Map

Related Raf Products

Tags: buy Sorafenib | Sorafenib supplier | purchase Sorafenib | Sorafenib cost | Sorafenib manufacturer | order Sorafenib | Sorafenib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID